- Jurgen Windeler, lecturera,
- Stefan Lange, research assistantb
- a Institut fur Medizinische Biometrie, Ruprecht-Karls-Universitat Heidelberg, Germany
- b Abteilung Medizinische Informatik und Biomathematik, Ruhr-Universitat Bochum, Germany
- Correspondence to: Dr Windeler, Institut fur Medizinische Biometrie, Ruprecht-Karls-Universitat, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany.
- Accepted 30 September 1994
In 1982 a new measure was introduced in research into osteoporosis and is now used everywhere in the literature. The so called “fracture rate” relates the number of fractures (single in some patients, multiple in others) to the cumulative time of observation of all patients. This concept, however, has no sound basis. Counting events instead of patients usually violates basic statistical assumptions and invalidates the use of common statistical tests and estimators. Its clinical interpretation is rather dubious. The use of such a measure impedes the search for valid and clinically meaningful outcome criteria and should be abandoned.
The concepts of design and analysis of randomised clinical trials seem to be well known to most researchers in clinical medicine. Randomisation, double blinding, definition of a primary end point, and prior calculation of power and sample size are widely accepted criteria for the quality of a clinical trial. There are additional problems, however, one of them being the handling of drop outs and missing information about them. Despite the favoured concept of intention to treat1 2 these problems have not gained adequate attention or—what is worse—have produced inadequate and invalid solutions.
We came to know one “solution” when we reviewed several trials concerning the treatment of osteoporosis,3 4 5 6 7 8 9 10 but there are other topics of research in which a similar procedure can be observed.11 12
The problem
Suppose that a clinical trial is performed to compare a new drug versus placebo with some binary end point. This may be death, myocardial infarction, recurrence of cancer, or any other criterion of success or failure. In the case of osteoporosis this is the occurrence of new (vertebral) fractures. We will assume a three year treatment and observation period with the primary end point of the trial being …
Sign in
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record







CiteULike
Connotea
Del.icio.us
Digg
Facebook
Mendeley
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: Bringing Nightingale down to size
Published 29 May 2012
Re: Avoid antimuscarinic drugs in people with dementia
Published 29 May 2012
Re: Strengthening primary health care: Related to the integration of medical training, community service need and health administration
Published 29 May 2012
Re: Strengthening primary health care: Related to the integration of medical training, community service need and health administration
Published 29 May 2012
Health Literacy: Patient involvement and engagement with healthcare
Published 29 May 2012
Most responses
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 (12 responses)
Published 10 May 2012 - 23:32
The psychiatric oligarchs who medicalise normality (9 responses)
Published 2 May 2012 - 15:42
Are doctors justified in taking industrial action in defence of their pensions? No (8 responses)
Published 8 May 2012 - 12:21
Are doctors justified in taking industrial action in defence of their pensions? Yes (8 responses)
Published 8 May 2012 - 12:21
The hardest thing: admitting error (7 responses)
Published 2 May 2012 - 12:27